CyFlow™ CD22 PE

CyFlow™ CD22 PE
Laser: Blue, Green, Yellow
Target Species: Human
Antigen: CD22
Field of Interest: Immunophenotyping
Clone: S-HCL-1
Regulatory Status: RUO
Alternative Name: BL-CAM, SIGLEC-2, SIGLEC2
Application: Flow cytometry
Format/Fluorochrome: PE
Species of Origin: Mouse
Clonality: monoclonal
Emission Maximum: 576 nm
Excitation Maximum: 496 nm, 565 nm
Isotype: IgG2b
Product number: CS494603

For Research Use Only

$255.00 USD*

Price excludes any applicable taxes plus shipping costs

HLDA Workshop HLDA IV—WS Code B48 Concentration Quantity 100 tests Volume 1.0... more
CyFlow™ CD22 PE
HLDA WorkshopHLDA IV—WS Code B48
Quantity100 tests
Volume1.0 mL
ImmunogenWhole hairy cell leukemia cells and membrane preparation
Background InformationCD22 (Siglec-2; sialic acid-binding immunoglobulin-like lectin-2) is a transmembrane glycoprotein binding α 2,6-linked sialic acid-bearing ligands. Intracellular domain of CD22 recruits protein tyrosine phosphatase SHP-1 through the immunoreceptor tyrosine-based inhibitory motifs (ITIMs), thus setting a treshold for B cell receptor-mediated activation. CD22 also regulates B-cell response by involvement in controlling the CD19/CD21-Src-family protein tyrosine kinase amplification pathway and CD40 signaling. CD22 exhibits hallmarks of clathrin-mediated endocytic pathway.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 10·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.

Specific References

| Foon KA, Todd RF rd: Immunologic classification of leukemia and lymphoma. Blood. 1986·Jul; 68(1):11324. <·PMID:·2809561·> | Huang J, Fan G, Zhong Y, Gatter K, Braziel R, Gross G, Bakke A: Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B‑Cell chronic lymphoproliferative disorders from admixed benign B cells in four‑color multiparameter flow cytometry. Am·J·Clin·Pathol. 2005·Jun; 123(6):826‑32. <·PMID:·15899772·> | James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, Raubitschek AA, Forman SJ, Press OW: Antigen sensitivity of CD22‑specific chimeric TCR is modulated by target epitope distance from the cell membrane. J·Immunol. 2008·May·15; 180(10):7028‑38. <·PMID:·18453625·> | Reineks EZ, Osei ES, Rosenberg A, Auletta J, Meyerson HJ: CD22 expression on blastic plasmacytoid dendritic cell neoplasms and reactivity of anti‑CD22 antibodies to peripheral blood dendritic cells. Cytometry·B·Clin·Cytom. 2009·Jul; 76(4):237‑48. <·PMID:·19382197·>

Article successfully added.